MedTrace Logo

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

NCT04770922 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-02-16

No results posted yet for this study

Summary

This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.

Conditions

  • Acute Lymphoblastic Leukemia, Pediatric
  • Adverse Drug Event

Sponsors & Collaborators

Principal Investigators

  • Kathleen M Sakamoto, MD, PhD · Stanford University

  • Stephanie M Smith, MD · Stanford University

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2021-08-30
Completion
2021-11-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770922 on ClinicalTrials.gov